Michael Shih is the founder of NeoPhore. NeoPhore has raised $40M in total funding. Latest round: Series B. Based in Altrincham, Cheshire, United Kingdom.
Michael Shih is the Chief Executive Officer of NeoPhore, a drug-discovery company focused on DNA mismatch repair / neoantigen-related cancer therapeutics. He was appointed CEO in December 2024 following the company's oversubscribed Series B financing.
Full founder directory · Investor directory · Company funding database · Fundraising library